Napo Pharmaceuticals, based in San Francisco, CA, is dedicated to developing and commercializing prescription medicines that provide essential supportive care for individuals undergoing treatment for diseases like cancer. Their focus is on addressing treatment-related gastrointestinal distress, particularly overactive bowel symptoms such as chronic diarrhea, urgency, and incontinence.
With a mission to enhance comfort, quality of life, and dignity for patients, Napo Pharmaceuticals is actively conducting Phase 3 clinical trials for Mytesi crofelemer to prevent chemotherapy-induced overactive bowel. They also support investigator-initiated studies for rare disease indications, all while prioritizing environmental sustainability and responsible harvesting practices from rainforest regions.
Generated from the website